Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy

L Straten; Avinash Dinmohamed; PE Westerweel; Ton Langerak; J Riedl; Jeanette Doorduijn; AP Kater; MD Levin

doi:10.1080/10428194.2018.1452215

Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy

L Straten, Avinash Dinmohamed, PE Westerweel, Ton Langerak, J Riedl, Jeanette Doorduijn, AP Kater, MD Levin

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	2757-2761
Number of pages	5
Journal	Leukemia & Lymphoma
Volume	59
Issue number	11
DOIs	https://doi.org/10.1080/10428194.2018.1452215
Publication status	Published - 2018

Research programs

EMC MM-02-72-01
EMC MM-02-72-02
EMC NIHES-02-65-02

Access to Document

10.1080/10428194.2018.1452215

http://hdl.handle.net/1765/105762

Cite this

Straten, L., Dinmohamed, A., Westerweel, PE., Langerak, T., Riedl, J., Doorduijn, J., Kater, AP., & Levin, MD. (2018). Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy. Leukemia & Lymphoma, 59(11), 2757-2761. https://doi.org/10.1080/10428194.2018.1452215

@article{bfcca244dbb54ed0a6cd2f816ecd4cca,

title = "Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy",

author = "L Straten and Avinash Dinmohamed and PE Westerweel and Ton Langerak and J Riedl and Jeanette Doorduijn and AP Kater and MD Levin",

year = "2018",

doi = "10.1080/10428194.2018.1452215",

language = "Undefined/Unknown",

volume = "59",

pages = "2757--2761",

journal = "Leukemia & Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "11",

}

Straten, L, Dinmohamed, A, Westerweel, PE, Langerak, T, Riedl, J, Doorduijn, J, Kater, AP & Levin, MD 2018, 'Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy', Leukemia & Lymphoma, vol. 59, no. 11, pp. 2757-2761. https://doi.org/10.1080/10428194.2018.1452215

Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy. / Straten, L; Dinmohamed, Avinash; Westerweel, PE et al.
In: Leukemia & Lymphoma, Vol. 59, No. 11, 2018, p. 2757-2761.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy

AU - Straten, L

AU - Dinmohamed, Avinash

AU - Westerweel, PE

AU - Langerak, Ton

AU - Riedl, J

AU - Doorduijn, Jeanette

AU - Kater, AP

AU - Levin, MD

PY - 2018

Y1 - 2018

U2 - 10.1080/10428194.2018.1452215

DO - 10.1080/10428194.2018.1452215

M3 - Article

C2 - 29616852

SN - 1042-8194

VL - 59

SP - 2757

EP - 2761

JO - Leukemia & Lymphoma

JF - Leukemia & Lymphoma

IS - 11

ER -